

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office		Atty. Dkt. No.	M#	Client Ref.
			0279190	2000-30-0155A
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Peter BRAMS <i>ATTACHED TO 10/14/03</i>		
		Appln. No.: 09/805,217		
		Filing Date: March 14, 2001		
Date: October 16, 2003	Page	1	of	3
		Examiner: L. Helms		Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
<i>LA</i>	AR 6,020,153	02/2000	Hardman et al.			
	BR					
	CR					
	DR					

FOREIGN PATENT DOCUMENTS

CREATOR TYPE						Abstract		Readily Available		
		Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclose	No
LA	ER	WO 99/33522		PCT						
	FR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

<i>LA</i>	GR	Umeda et al., "Effective production of monoclonal antibodies against phosphatidylserine: Stereo-specific recognition of phosphatidylserine by monoclonal antibodies," <i>J Immunol.</i> , 1989, 143(7):2273-2279.			
	HR	Bakimer et al., "Antiphospholipid syndrome and the idiotypic network," <i>Lupus.</i> , 1995, 4:204-208.			
	IR	Miyazawa et al., "Monoclonal antibody analysis of phosphatidylserine and protein kinase C localizations in developing rat cerebellum," <i>J Neurochem.</i> , 1992, 59(4):1547-1554.			
	JR	Hosomi et al., "Simple purification method of the antiphospholipid antibody from normal human plasma," <i>Exp. Clin. Immunogenetics</i> , 1997, 14:281-285.			
	KR	Adler et al., "Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR," <i>Biol. Reprod.</i> , 1995, 53:905-910.			
	LR	Reza et al., "Anti-idiotypic monoclonal antibody recognizes a consensus recognition site for phosphatidylserine in phosphatidylserine-specific monoclonal antibody and protein kinase C," <i>FEBS</i> , 1994, 339(3):229-33.			
	MR	Igarashi et al., "Specific binding of a synthetic peptide derived from an antibody complementarity determining region to phosphatidylserine," <i>J Biochem.</i> , 1995, 117(2):452-7.			
	NR	Mitchison, "The carrier effect in the secondary response to haptenprotein conjugates," <i>Eur. J. Immunol.</i> , 1971, 1:18-25.			
	OR	Claman and Chaperon, "Immunologic complementation between thymus and marrow cells -- a model for the two-cell theory of immunocompetence," <i>Transplant Rev.</i> , 1969, 1:92-119.			
<i>LA</i>	PR	Katz et al., "Cell interactions between histoincompatible T and B lymphocytes. The H-2 gene complex determines successful physiologic lymphocyte interactions," <i>Proc. Natl. Acad. Sci. USA</i> , 1973, 70:2624-2629.			
<i>LA</i>	QR	Raff et al., "Role of thymus-derived lymphocytes in the secondary humoral immune response in mice," <i>Nature</i> , 1970, 226:1257-1260.			

RR	Fadok et al., "Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages," <i>J. Immunol.</i> , 1992, 148:2207-2216.				
SR	Martin et al., "Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl," <i>J. Exp. Med.</i> , 1995, 182:1545-1556.				
TR	Koopman et al., "Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis," <i>Blood</i> , 1994, 84:1415-1420.				
UR	Utsugi et al., "Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes," <i>Cancer Res.</i> , 1991, 51:3062-3066.				
VR	VanDeWater et al., "Tumor cell generation of thrombin via functional prothrombinase assembly," <i>Cancer Res.</i> , 1985, 45:5521-5525.				
WR	Sugimura et al., "Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces," <i>Blood Coagul. Fibrin.</i> , 1994, 5:365-373.				
XR	Rao et al., "Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity," <i>Thromb. Res.</i> , 1992, 67:517-531.				
YR	Zwaal et al., "Pathophysiologic implications of membrane phospholipid asymmetry in blood cells," <i>Blood</i> , 1997, 89:1121-1132.				
ZR	Zwaal et al., "Loss of membrane phospholipid asymmetry during activation of blood platelets and sickled red cells; mechanisms and physiological significance," <i>Mol. Cell Biochem.</i> , 1989, 91:23-31.				
AAR	Bervers et al., "Changes in membrane phospholipid distribution during platelet activation," <i>Biochim. Biophys. Acta</i> , 1983, 736:57-66.				
BBR	Qu et al., "Phosphatidylserine-mediated adhesion of T-cells to endothelial cells," <i>Biochem J.</i> , 1996, 317:343-346.				
CCR	Katsuragawa et al., "Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion," <i>Biol Reprod.</i> , 1997, 56:50-58.				
DDR	Katsuragawa et al., "Monoclonal antiphosphatidylserine antibody reactivity against human first-trimester placental trophoblasts," <i>Am. J. Obstet. Gynecol.</i> , 1995, 172:1592-1597.				
EER	Rand et al., "Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion," <i>Am. J. Obstet. Gynecol.</i> , 1994, 171:1566-1572.				
FFR	Savill et al., "Phagocyte recognition of cells undergoing apoptosis," <i>Immunol. Today</i> , 1993, 14:131-136.				
GGR	Hannun et al., "Apoptosis and the dilemma of cancer chemotherapy," <i>Blood</i> , 1997, 89:1845-1853.				
HHR	Fadok et al., "Apoptosis: getting rid of the bodies," <i>Current Biology</i> , 1998, 8(19):R693-5.				
IIR	Asherson et al., "Antiphospholipid syndrome," <i>J. Invest. Dermatol.</i> , 1993, 100:21S-27S.				
JJR	Mackworth-Young et al., "Antiphospholipid antibodies: more than just a disease marker?" <i>Immunol. Today</i> , 1990, 11:60-65.				
KKR	Matsuura et al., "Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease," <i>Lancet</i> , 1990, 336:177-178.				
LLR	Roubey et al., "Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies," <i>Blood</i> , 1994, 84:2854-2867.				
MMR	Triplett et al., "Antiphospholipid-protein antibodies: laboratory detection and clinical relevance," <i>Thromb. Res.</i> , 1995, 78:1-31.				
NNR	Becker et al., "Antiphospholipid syndrome associated with immunotherapy for patients with melanoma," <i>Cancer</i> , 1994, 73:1621-1624.				
OOR	Naldi et al., "Antiphospholipid antibodies and melanoma: a link?" <i>Dermatology</i> , 1992, 184:156.				

PPR	Herstoff et al., "Cutaneous lupus erythematosus associated with melanoma and BCG vaccine therapy," <i>Archives of Dermatology</i> , 1979, 115:856-859.			
QQR	Fishman et al., "Vitiligo autoantibodies are effective against melanoma", <i>Cancer</i> , 1993, 72:2365-2369.			
RRR	Diaz et al., "Synthesis of disulfide-containing phospholipid analogs for the preparation of head group-specific lipid antigens: generation of phosphatidylserine antibodies," <i>Bioconjug Chem.</i> , 1998, 9:250-254.			
SSR	Pagano et al., "Lipid traffic in eukaryotic cells: mechanisms for intracellular transport and organelle-specific enrichment of lipids," <i>Current Opinion in Cell Biology</i> , 1990, 2:652-663.			
TTR	Tang et al., "A subfamily of P-type ATPases with aminophospholipid transporting activity," <i>Science</i> , 1996, 272:1495-1497.			
UUR	Connor et al., "Exposure of phosphatidylserine in the outer leaflet of human red blood cells. Relationship to cell density, cell age, and clearance by mononuclear cells," <i>J. Biol. Chem.</i> , 1994, 269:2399-2404.			
VVR	Boas et al., "Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia," <i>Proc. Natl. Acad. Sci. (USA)</i> , 1998, 95:3077-3081.			
WWR	Geldwerth et al., "Transbilayer mobility and distribution of red cell phospholipids during storage," <i>J. Clin. Invest.</i> , 1993, 92:308-314.			
XXR	Morrison et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> , 1984, 81:6851-5.			
YYR	Morrison et al., "Genetically engineered antibody molecules," <i>Adv. Immunol.</i> , 1988, 44:65-92.			
ZZR	Verhoeven et al., "Reshaping human antibodies: grafting an antilysozyme activity," <i>Science</i> , 1988, 239:1534-1536.			
AAAR	Padlan, "A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties," <i>Molec. Immun.</i> , 1991, 28:489-498.			
BBBR	Padlan, "Review: Anatomy of the antibody molecule," <i>Molec. Immun.</i> , 1994, 31:169-217.			
CCCR	Brams et al., "In vitro B-lymphocyte antigen priming against both non-immunogenic and immunogenic molecules requiring low amounts of antigen and applicable in hybridoma technology," <i>J. Immunol. Methods</i> , 1987, 98:11-22.			
DDDR	Balasubramanian et al., "Immune clearance of phosphatidylserine-expressing cells by phagocytes. The role of beta2-glycoprotein I in macrophage recognition," <i>J. Biol. Chem.</i> , 1997, 272:31113-31117.			
EEER	Elliot et al., "Amino acid sequence diversity in mouse $\lambda 2$ variable regions," <i>J. Immunol.</i> , 1984, 133:2757-2761.			
FFFR	Geffer et al., "Analysis of the anti-azobenzenearsonate response at the molecular level," <i>Ann. Immunol. (Inst. Pasteur)</i> , 1984, 135 C:17-30.			

Examiner

Date Considered: 11/3/03

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.